Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Rhythm Pharmaceuticals Inc RYTM.OQ reported a quarterly adjusted loss of 75 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -69 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 68 cents per share. Wall Street expected results to range from -88 cents to -49 cents per share.

• Revenue rose 66.8% to $48.50 million from a year ago; analysts expected $43.63 million.

• Rhythm Pharmaceuticals Inc's reported EPS for the quarter was a loss of 75 cents​.

• The company reported a quarterly loss of $47.98 million.

• Rhythm Pharmaceuticals Inc shares had risen by 42.8% this quarter and gained 61.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.7% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $103.50, about 12.8% above its last closing price of $90.24

This summary was machine generated from LSEG data August 5 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)